Pulmonary Arterial Hypertension: Pathophysiology and Treatment.

Lan, Norris S H; Massam, Benjamin D; Kulkarni, Sandeep S; Lang, Chim C.

Afiliação

Lan NSH; School of Medicine and Pharmacology, University of Western Australia, Perth 6009, Australia. 21151851@student.uwa.edu.au.
Massam BD; School of Medicine and Pharmacology, University of Western Australia, Perth 6009, Australia. 21139507@student.uwa.edu.au.
Kulkarni SS; School of Medicine and Pharmacology, University of Western Australia, Perth 6009, Australia. 21113058@student.uwa.edu.au.
Lang CC; Division of Molecular and Clinical Medicine, Mailbox 2, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK. c.c.lang@dundee.ac.uk.

Diseases ; 6(2)2018 May 16.

Article em En | MEDLINE | ID: mdl-29772649

Palavras-chave

endothelin receptor antagonists; endothelin-1; mortality; nitric oxide; phosphodiesterase-5 inhibitor; prostacyclin analogues; prostacyclin receptor agonists; prostacyclin-thromboxane; pulmonary arterial hypertension; soluble guanylate cyclase stimulators

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article